Neurocrine Biosciences
NBIX
#1415
Rank
NZ$21.31 B
Marketcap
$210.55
Share price
1.42%
Change (1 day)
7.88%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.28. In 2022 the company made an earnings per share (EPS) of $2.70 an increase over its 2021 EPS that were of $1.59.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2219.52%
2022$2.7069.47%
2021$1.59-78.21%
2020$7.30990%
2019$0.6781.82%
2018$0.37-113.5%
2017-$2.730.62%
2016-$2.7157.28%
2015-$1.7225.61%
2014-$1.3718.84%
2013-$1.16-1085.71%
2012$0.12-89.71%
2011$1.14-500%
2010-$0.28-86.92%
2009-$2.18-43.48%
2008-$3.85-57.8%
2007-$9.1392.58%
2006-$4.74371.67%
2005-$1.00-52.76%
2004-$2.1336.56%
2003-$1.56-70%
2002-$5.19118.31%
2001-$2.388.4%
2000-$2.1948.86%
1999-$1.47-20%
1998-$1.84-479.31%
1997$0.49

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.50 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.92-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.96-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.09 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.16 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.11-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.79-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.07-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA